BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 20374272)

  • 1. BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma.
    Sterz J; Jakob C; Kuckelkorn U; Heider U; Mieth M; Kleeberg L; Kaiser M; Kloetzel PM; Sezer O; von Metzler I
    Eur J Haematol; 2010 Aug; 85(2):99-107. PubMed ID: 20374272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
    Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
    Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The peptide-semicarbazone S-2209, a representative of a new class of proteasome inhibitors, induces apoptosis and cell growth arrest in multiple myeloma cells.
    Baumann P; Müller K; Mandl-Weber S; Leban J; Doblhofer R; Ammendola A; Baumgartner R; Oduncu F; Schmidmaier R
    Br J Haematol; 2009 Mar; 144(6):875-86. PubMed ID: 19170678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).
    Yin D; Zhou H; Kumagai T; Liu G; Ong JM; Black KL; Koeffler HP
    Oncogene; 2005 Jan; 24(3):344-54. PubMed ID: 15531918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. All-trans retinoic acid can intensify the growth inhibition and differentiation induction effect of rosiglitazone on multiple myeloma cells.
    Huang H; Wu D; Fu J; Chen G; Chang W; Chow HC; Leung AY; Liang R
    Eur J Haematol; 2009 Sep; 83(3):191-202. PubMed ID: 19467017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis.
    Park WH; Seol JG; Kim ES; Hyun JM; Jung CW; Lee CC; Kim BK; Lee YY
    Cancer Res; 2000 Jun; 60(11):3065-71. PubMed ID: 10850458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TP-110, a new proteasome inhibitor, down-regulates IAPs in human multiple myeloma cells.
    Iijima M; Momose I; Ikeda D
    Anticancer Res; 2009 Apr; 29(4):977-85. PubMed ID: 19414335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
    von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O
    Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
    Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
    Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
    Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
    Meister S; Schubert U; Neubert K; Herrmann K; Burger R; Gramatzki M; Hahn S; Schreiber S; Wilhelm S; Herrmann M; Jäck HM; Voll RE
    Cancer Res; 2007 Feb; 67(4):1783-92. PubMed ID: 17308121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms.
    Zhang S; Suvannasankha A; Crean CD; White VL; Johnson A; Chen CS; Farag SS
    Clin Cancer Res; 2007 Aug; 13(16):4750-8. PubMed ID: 17699852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Syrbactin class proteasome inhibitor-induced apoptosis and autophagy occurs in association with p53 accumulation and Akt/PKB activation in neuroblastoma.
    Archer CR; Koomoa DL; Mitsunaga EM; Clerc J; Shimizu M; Kaiser M; Schellenberg B; Dudler R; Bachmann AS
    Biochem Pharmacol; 2010 Jul; 80(2):170-8. PubMed ID: 20362557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL.
    Romagnoli M; Desplanques G; Maïga S; Legouill S; Dreano M; Bataille R; Barillé-Nion S
    Clin Cancer Res; 2007 Oct; 13(20):6010-8. PubMed ID: 17947462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of protein kinase C sensitise multiple myeloma cells to common genotoxic drugs.
    Baumann P; Armann J; Mandl-Weber S; Grün G; Oduncu F; Schmidmaier R
    Eur J Haematol; 2008 Jan; 80(1):37-45. PubMed ID: 18028419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimyeloma effects of a sesquiterpene lactone parthenolide.
    Suvannasankha A; Crean CD; Shanmugam R; Farag SS; Abonour R; Boswell HS; Nakshatri H
    Clin Cancer Res; 2008 Mar; 14(6):1814-22. PubMed ID: 18347184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis.
    Goel A; Dispenzieri A; Greipp PR; Witzig TE; Mesa RA; Russell SJ
    Exp Hematol; 2005 Jul; 33(7):784-95. PubMed ID: 15963854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.